RIPRETINIB - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for ripretinib and what is the scope of patent protection?

Ripretinib is the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are thirty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ripretinib has eighty-seven patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for RIPRETINIB

International Patents:	87
US Patents:	35
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	12
Patent Applications:	112
What excipients (inactive ingredients) are in RIPRETINIB?	RIPRETINIB excipients list
DailyMed Link:	RIPRETINIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RIPRETINIB

Generic Entry Date for RIPRETINIB^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RIPRETINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1/Phase 2
Asan Medical Center	Phase 2
Theseus Pharmaceuticals	Phase 1/Phase 2

See all RIPRETINIB clinical trials

Pharmacology for RIPRETINIB

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C8 Inhibitors P-Glycoprotein Inhibitors Platelet-derived Growth Factor alpha Receptor Inhibitors Stem Cell Factor (KIT) Receptor Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for RIPRETINIB

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for RIPRETINIB

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for RIPRETINIB

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Deciphera Pharmaceuticals (Netherlands) B.V.	Qinlock	ripretinib	EMEA/H/C/005614 Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.	Authorised	no	no	yes	2021-11-18
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for RIPRETINIB

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Korea	20090067175	KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES	⤷ Sign Up
European Patent Office	4013335	SYSTÈME D'ORIENTATION RACHIDIEN (SPINAL ORIENTATION SYSTEM)	⤷ Sign Up
Japan	2023509629	非晶質キナーゼ阻害剤の製剤およびその使用方法	⤷ Sign Up
Brazil	122012012032	Usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas	⤷ Sign Up
Brazil	PI0716844	INIDORES DE QUINASE ÚTEIS PARA O TRATAMENTO DE DOENÇAS PROLIFERATIVAS	⤷ Sign Up
European Patent Office	4084778	FORMULATIONS D'INHIBITEUR DE KINASE AMORPHE ET LEURS PROCÉDÉS D'UTILISATION (AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF)	⤷ Sign Up
China	101553232	Kinase inhibitors useful for the treatment of proliferative diseases	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.